Intravitreal Therapeutics Utilization in 2023

Related

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial

  Gustavo Barreto de Melo, MD, PhD, FASRS

  Annual Meeting Talks

  2020

• 

  Predictors of Post-injection Endophthalmitis: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength

  Tarek S. Hassan, MD, FASRS

  Updates from the Field

  2019